Moleculin Biotech (NASDAQ:MBRX) Stock Crosses Below Fifty Day Moving Average – Should You Sell?

Moleculin Biotech, Inc. (NASDAQ:MBRX) passed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $2.54 and traded as low as $2.09. Moleculin Biotech shares last traded at $2.19, with a volume of 110,270 shares traded.

Analyst Upgrades and Downgrades

Several analysts have commented on MBRX shares. Wall Street Zen cut Moleculin Biotech from a “sell” rating to a “strong sell” rating in a report on Saturday, May 16th. Weiss Ratings reissued a “sell (e+)” rating on shares of Moleculin Biotech in a research report on Friday, July 17th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Moleculin Biotech currently has an average rating of “Hold” and a consensus price target of $22.00.

Moleculin Biotech Stock Down 37.9%

The company’s fifty day moving average is $2.51 and its 200 day moving average is $2.81. The stock has a market cap of $7.26 million, a PE ratio of -0.08 and a beta of 1.75.

Moleculin Biotech (NASDAQ:MBRX) last released its quarterly earnings data on Thursday, May 14th. The company reported ($3.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.33) by ($1.21). Equities analysts expect that Moleculin Biotech, Inc. will post -5.1 EPS for the current year.

Institutional Trading of Moleculin Biotech

A hedge fund recently bought a new position in Moleculin Biotech stock. Jane Street Group LLC purchased a new stake in Moleculin Biotech, Inc. (NASDAQ:MBRX) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor purchased 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned approximately 1.11% of Moleculin Biotech at the end of the most recent quarter. 15.52% of the stock is owned by hedge funds and other institutional investors.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.